News

Coronavirus: AstraZeneca resumes vaccine trials in Great Britain

The pharmaceutical giant explained that it has been authorized to resume the trial by all British regulatory bodies

RAI News – 12 September 2020

The pharmaceutical group AstraZeneca has resumed clinical trials in the UK of the anti-Covid vaccine developed by the University of Oxford. The tests had been halted after a volunteer fell ill. The pharmaceutical giant explained that it has been authorized to resume the trial by all British regulatory bodies.

The investigation by the independent Committee has concluded and, therefore, following the recommendations of the experts and of the Medicines Health Regulatory Authority (Mhra), the British regulatory body which gave the go-ahead not detecting safety problems, clinical trials will start again in the whole country.

So far there are about 18 thousand volunteers who have received the administration of the vaccine.

"Good news. The Oxford / Astra Zeneca vaccine trial against Covid-19 resumes ". This is the comment of the virologist of the San Raffaele University of Milan, Roberto Burioni, who in a post on Facebook reconstructs what may have led to the rapid resumption of the clinical trial suspended on 6 September due to a serious side effect in a participant at the studio.

Burioni writes: “From journalistic sources we learn that the clinical trial of the vaccine against COVID-19 developed by the University of Oxford, blocked a few days ago after a study participant had suffered a serious side effect (we talked about it in Medical Facts), restarts.

What could have happened? When something like this happens – simplifying as much as possible – an independent evaluation committee meets which takes into consideration all the data and decides whether the side effect can be due to the vaccine or not.

In this case we can imagine that this committee thought that the side effect was not due to the vaccine, or that its magnitude was much milder than what was filtered through the press.

Unfortunately we don't have any official data, if not the meager press releases from pharmaceutical companies. We don't even know anything for sure about the disorders accused by the patient, their seriousness, the clinical progress.

However, let us remember that doctors with a great reputation sit on these committees and are not willing to risk it, so I would tend to trust them.

Let's cross our fingers and hope there are no more hiccups. Meanwhile let's be careful, distance and mask“.

Related news: The Italian woman who negotiates with BigPharma to ensure the vaccine for Europe

The Vaccine of the Non-Aligned. Reserve one billion doses of Sputnik V in 20 countries. It will be produced in 5 countries in addition to Russia

 

Redazione Fedaiisf

Promote the cohesion and union of all members to allow a univocal and homogeneous vision of the professional problems inherent in the activity of pharmaceutical sales reps.

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco